4D hires a trio of area heads as it ramps up its gene therapy pipeline
4D Molecular Therapeutics raised $75 million in June to get several gene therapy programs into and through the clinic. Now, it’s adding a trio of executives to spearhead its work in heart, eye and lung diseases as it looks to shepherd treatments in those focus areas forward.